TRVX.OL

Targovax ASA is a clinical-stage immuno-oncology firm focused on creating immune-stimulating therapies to tackle difficult-to-treat solid cancers. Its primary drug candidate, ONCOS-102, is currently undergoing Phase I/II clinical trials for indications such as mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines specifically targeting mutant KRAS cancers and is progressing ONCOS-211 as a next-generation ONCOS virus. Targovax has established several collaborative agreements, including partnerships with the Cancer Research Institute and Ludwig Cancer Research to advance ONCOS-102 for colorectal cancer with peritoneal carcinomatosis, with Valo Therapeutics to apply mutant RAS neoantigen coatings to ONCOS viruses using PeptiCRAd technology, and with Papyrus Therapeutics to engineer innovative ONCOS viruses featuring Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was founded in 2010 and is headquartered in Lysaker, Norway.